The lancet oncology
-
The lancet oncology · Aug 2011
Randomized Controlled Trial Multicenter Study Comparative StudyErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Activating mutations in EGFR are important markers of response to tyrosine kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study compared efficacy and tolerability of the TKI erlotinib versus standard chemotherapy in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ⋯ F Hoffmann-La Roche Ltd (China); Science and Technology Commission of Shanghai Municipality.
-
The lancet oncology · Aug 2011
Randomized Controlled Trial Multicenter StudyBortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Bortezomib and rituximab have shown additive activity in preclinical models of lymphoma, and have been shown to be active and generally well tolerated in a randomised phase 2 study in patients with follicular and marginal zone lymphoma. We compared the efficacy and safety of rituximab alone or combined with bortezomib in patients with relapsed or refractory follicular lymphoma in a phase 3 setting. ⋯ Johnson & Johnson Pharmaceutical Research & Development and Millennium Pharmaceuticals, Inc.